Reduction of estimated fluid volumes following initiation of empagliflozin in patients with type 2 diabetes and cardiovascular disease: a secondary analysis of the placebo-controlled, randomized EMBLEM trial

Reduction of estimated fluid volumes following initiation of empagliflozin in patients with type 2 diabetes and cardiovascular disease: a secondary analysis of the placebo-controlled, randomized EMBLEM trial

Abstract Backgrounds/Aim Sodium glucose co-transporter 2 inhibitors promote osmotic/natriuretic diuresis and reduce excess fluid volume, and this improves cardiovascular outcomes, including hospitalization for heart failure. We sought to assess the effect of empagliflozin on estimated fluid volumes...

Full description

Bibliographic Details
Main Authors: Atsushi Tanaka, Michio Shimabukuro, Hiroki Teragawa, Yosuke Okada, Toshinari Takamura, Isao Taguchi, Shigeru Toyoda, Hirofumi Tomiyama, Shinichiro Ueda, Yukihito Higashi, Koichi Node, the EMBLEM Investigators
Format: Article
Language:English
Published: BMC 2021-06-01
Series:Cardiovascular Diabetology
Subjects:
Fluid volume
Empagliflozin
Heart failure
Type 2 diabetes
Cardiovascular disease
N-terminal pro-brain natriuretic peptide
Online Access:https://doi.org/10.1186/s12933-021-01295-6

Internet

https://doi.org/10.1186/s12933-021-01295-6

Similar Items